On the filings, Cigna (CI) is the stronger stock right now — higher on our blended fundamentals-plus-verdict read, and we currently rate it BUY.
A its multiple flatters a profit collapse, but its multiple and $10.6B operating cash flow make CVS a cheap, cash-rich hold — not a sell.
Deep-value health giant at 12.6x EPS and its multiple — cheap, cash-rich, buying back stock, but razor-thin margins and PBM overhang cap the upside.
| Metric | CVS | CI |
|---|---|---|
| Fundamentals score | 54 | 68 |
| Revenue growth (YoY) | +7.8% | +11.2% |
| Net income growth (YoY) | -61.7% | +73.5% |
| Net margin | 0.4% | 2.2% |
| Return on equity | 2.4% | 14.3% |
| ROIC (est.) | 2.5% | 17.2% |
| Liabilities / Equity | 2.37 | 2.78 |
| Piotroski F-score | 6 / 9 | 7 / 9 |
Bold green = the stronger figure. All rows derive from SEC XBRL filings — no market-price data on this page.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 19, 2026, 2:21 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 11:29 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.